(Total Views: 587)
Posted On: 06/24/2022 9:08:56 AM
Post# of 154130
Re the 700 results. Seems like the most obvious answer -- other than Amarex making another cameo appearance as the Evil twisted-mouth one-hipped Scientist -- is what we have come to call the Curse of the Nader: sample size. It happened in CD10, in spades in CD12, in our bid for BTD for TNBC, and now it could be the culprit in NASH 700.
Not hard to understand NP's zeal to go for everything. The drug works, and it doesn't just work on one indication. But that zeal shrank the size of ALL the trials down to the point where a little misstep or a piece of bad luck (too many old people in the Leron arm of CD12; too many healthy people in the SOC wing of CD10) could blow up our results. And so here we are.
This is why we need a partner. We want a big fat trial conducted quickly, if it can be, for something. We can't pay for it. Let the buyers bear (and bare) our wares.
Not hard to understand NP's zeal to go for everything. The drug works, and it doesn't just work on one indication. But that zeal shrank the size of ALL the trials down to the point where a little misstep or a piece of bad luck (too many old people in the Leron arm of CD12; too many healthy people in the SOC wing of CD10) could blow up our results. And so here we are.
This is why we need a partner. We want a big fat trial conducted quickly, if it can be, for something. We can't pay for it. Let the buyers bear (and bare) our wares.
(8)
(0)
